Cantor Fitzgerald reiterates Lam Research stock rating on AI demand By Investing.com

Cantor Fitzgerald reiterated an Overweight rating on Lam Research with a $320 price target, while lifting 2027 EPS estimates to $10 versus $7.78 consensus and 2028 EPS to $12 versus $8.86. The firm also raised its 2026 wafer fabrication equipment outlook to more than $140 billion from $135 billion, implying at least 27% growth, and highlighted strong gross margin execution at 50.5% for the June quarter. The stock has already rallied 301% over the past year and trades near its 52-week high.

Analysis

The key second-order effect is that LRCX is becoming a leverage play on a tighter, higher-quality capex cycle rather than just a top-line WFE rebound. If 2026 spend inflects as projected, the mix shift toward etch/deposition and upgrade-heavy customers should expand margins faster than unit growth alone would imply, because upgrades carry materially better economics and shorter qualification risk than greenfield tool placements. That matters because the market is still likely underestimating how much of the profit pool can migrate to the equipment layer when AI-driven memory and logic intensity force multiple process steps per wafer.

The bigger tell is the margin guide clearing a future target model, which usually resets investor expectations from “cyclical recovery” to “structural re-rating.” That opens room for estimate revisions to compound for several quarters, but it also means the stock can stay expensive while earnings catch up; in other words, valuation pain is likely to come not from a missed quarter but from any pause in capex ordering or digestion after an aggressive buildout. The most vulnerable link is end-market concentration: if hyperscaler AI spending slows, the upgrade cycle could still look healthy on paper while lead times and book-to-bill compress beneath the surface.

Consensus may be underappreciating how much operating leverage is already reflected in the bull case. The street can be right on fundamentals and still wrong on timing if the next leg up requires 2027/2028 earnings visibility that is not yet fully de-risked by customer purchase orders. The contrarian read is that the stock is more a quality cyclical compounder than a bargain, so upside from here likely depends on another round of forecast raises rather than multiple expansion.

For trading, the cleanest expression is to own LRCX against a weaker equipment basket or against fabs with less direct AI process intensity, because the relative earnings revisions should remain strongest where upgrade mix and margin leverage are highest. The near-term risk is a post-earnings digestion phase over the next 2-8 weeks if investors fade the guidance beat and rotate into cheaper semicap names. Over a 6-12 month horizon, the setup remains constructive unless WFE data rolls over materially, in which case the stock could de-rate quickly from premium to merely expensive.

Key Decisions for Investors

• Long LRCX vs short a semiconductor equipment basket for the next 3-6 months; thesis is that estimate revisions and margin leverage should concentrate in names with the best AI/process-node exposure, but stop if industry WFE bookings flatten for two consecutive months.
• Sell cash-secured puts on LRCX 10-15% below spot with 30-45 day tenor to monetize elevated valuation while expressing a willingness to own on a pullback; attractive if you expect continued upward earnings revisions but limited immediate multiple expansion.
• If already long, trim 20-30% into strength and re-add on any 8-12% drawdown; the stock is likely to trade like a premium compounder, not a straight-line momentum name, and pullbacks should remain buyable as long as guidance revisions continue.
• Consider a pairs trade long LRCX / short a less AI-sensitive equipment peer for 6-12 months; the edge is not just growth, but higher incremental gross margin from upgrades and manufacturing mix, which should drive better revision momentum.
• Avoid chasing outright longs after a vertical move unless you have a 12-month horizon; near-term risk/reward is skewed toward consolidation, while the cleaner upside is in structured entries on weakness or option structures.